You are viewing: North America Biobanking Market analysis
Part of: Biobanking Market (Global)

The North America Biobanking Market was valued at $3318.8 Million in 2025 and projected to reach to $5156.4 Million by 2030, representing a compound annual growth rate of 9.2%. North America's biobanking market is poised for sustained expansion through 2030, fueled by increasing adoption of precision medicine, growing demand for personalized therapeutics, and expanding genomic research programs across leading healthcare systems.

North America Biobanking Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America Biobanking Market Trends and Insights

  • North America's advanced healthcare infrastructure, strong regulatory frameworks, and significant investment in precision medicine are driving this expansion.
  • The region's leadership in genomic research and personalized medicine initiatives positions North America as a critical hub for biobanking innovation and development. North America's biobanking sector benefits from increasing demand for biological samples in clinical research, drug development, and diagnostic applications.
  • The region's well-established network of academic institutions, hospitals, and private biobanks supports the collection, storage, and management of biological specimens.
  • North America's growing focus on rare disease research and regenerative medicine further accelerates market growth during the 2025–2030 forecast period. Key drivers in North America include rising healthcare expenditures, expanding clinical trial activities, and heightened awareness of precision medicine benefits.
  • North America's regulatory environment, including FDA oversight and HIPAA compliance standards, ensures quality and ethical biobanking practices.
  • The region's competitive landscape features both established players and emerging biotech companies investing in advanced sample preservation and data management technologies..

Key Market Statistics

  • CAGR (2025-2030) 9.2% CAGR
  • Market Size, 2025 ~USD 3318.8 Million
  • Forecast, 2030 ~USD 5156.4 Million
  • Geography North America

North America Biobanking Market Overview

Market Leadership Position :

North America commands the largest share of the global biobanking market, with a 2025 valuation of $3,318.8 million, driven by the US market's dominance at $2,908.8 million and Canada's contribution of $534.6 million.

Strong Growth Trajectory :

The region is projected to grow from $3,318.8 million in 2025 to $5,156.4 million by 2030, representing a robust 9.2% CAGR, outpacing the global average of 9.1% and reflecting sustained investment in precision medicine infrastructure.

Precision Medicine & Genomics Hub :

North America's advanced healthcare infrastructure and leadership in genomic research position it as the epicenter for personalized medicine initiatives, with major academic institutions and biotech companies driving innovation in sample collection and storage technologies.

Regulatory Excellence & Investment :

Strong regulatory frameworks from the FDA and Health Canada, combined with significant venture capital and government funding for biobanking initiatives, create a favorable ecosystem for market expansion and technological advancement in the region.

North America Biobanking Market Dynamics

  • The region's mature healthcare infrastructure and robust regulatory environment provide a stable foundation for market growth, with significant investments from both public and private sectors accelerating innovation in sample management and data analytics. Key growth drivers include rising prevalence of chronic diseases, increasing clinical trial activities, and growing partnerships between biobanks and pharmaceutical companies.
  • The integration of artificial intelligence and advanced data management systems into biobanking operations is expected to enhance operational efficiency and drive market value.
  • North America's commitment to advancing precision medicine and personalized healthcare will continue to position the region as the global leader in biobanking market development..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • North America's biobanking market will grow from $3,318.8M (2025) to $5,156.4M (2030) at a 9.2% CAGR.
    • North America leads in precision medicine adoption, driving demand for high-quality biological sample repositories.
    • North America's robust regulatory framework and healthcare infrastructure support ethical and compliant biobanking operations.
    • North America's investment in genomic research and clinical trials accelerates biobank utilization and market expansion.

    Biobanking Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SOFTWARE (Offering)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.1% from 2025 to 2030
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 7.65 (2025)
    Revenue Forecast (Billions) ~USD 11.82 (2030)
    Segments Covered Offering, Type, Operation Type, Workflow, Sample Type, Ownership, Application, End User

    North America Biobanking Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services
    • Software

    By Type

    • Alarm & Monitoring Systems
    • Clinical Research
    • Consumables
    • Cryogenic Storage Systems
    • Equipment
    • Freezers & Refrigerators
    • Life Science Research
    • Life Sciences Research
    • Other Equipment & Accessories
    • Other Services
    • Physical Biobanking Services
    • Temperature & Humidity Control Systems
    • Thawing Equipment
    • Virtual Biobanking Services

    By Operation Type

    • Automated Equipment
    • Automated Operations
    • Manual Equipment
    • Manual Operations

    By Workflow

    • Sample Analysis
    • Sample Collection & Storage
    • Sample Processing
    • Transport & Logistics

    By Sample Type

    • Biological Fluids
    • Blood Products
    • Human Waste Products
    • Nucleic Acids
    • Solid Tissues & Organs
    • Stem Cells & Cell Lines

    By Ownership

    • Academic & Research Institution Biobanks
    • Hybrid/Ppp Model
    • National/Regional Agencies
    • Other Ownership Models
    • Private/ Commercial Biobanks

    By Application

    • Diagnostic Applications
    • Other Applications
    • Research Applications
    • Therapeutic Applications

    By End User

    • Academic & Research Institutes
    • Biobanks
    • Cros
    • Hospitals & Diagnostic Laboratories
    • Pharma-Biotech Companies & Cros

    Target Audience

    • Biobanking Service Providers : Biobank operators and sample management companies need North America market data to identify growth opportunities, benchmark performance against regional competitors, and develop expansion strategies in the US and Canadian markets.
    • Pharmaceutical & Biotech Companies : Drug developers and biotech firms require detailed market insights to assess biobanking partnerships, clinical trial sample sourcing capabilities, and precision medicine collaboration opportunities across North America.
    • Healthcare System Administrators : Hospital networks and healthcare providers need market intelligence to evaluate biobanking infrastructure investments, understand regulatory requirements, and align with precision medicine initiatives in their regions.
    • Investment & Private Equity Firms : Investors seeking biobanking sector opportunities require comprehensive North America market data, growth forecasts, and competitive landscape analysis to make informed funding and acquisition decisions.
    • Research Institutions & Academic Centers : Universities and research organizations need market insights to secure funding, understand biobanking infrastructure trends, and identify collaboration opportunities with commercial biobanking entities in North America.

    Key Companies in the North America Biobanking Market

    CompanyHQOwnershipStrongest segments
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx and STx instruments,ExPERT GTx and VLx instruments,Disposable processing assemblies (PAs),
    HDFC BANKIndiaPublic CompanyRetail Banking (deposits, consumer and home loans, cards),Wholesale Banking (corporate, SME, supply chain, trade),Treasury and Markets (money market, derivatives, investments),
    STANDARD CHARTEREDUnited KingdomPrivate CompanyFinancial Markets (FX, rates, commodities, credit),Transaction Banking (trade, cash, liquidity, custody),Corporate & Structured Finance,
    YES BANKIndiaPublic CompanyRetail banking (deposits, cards, consumer loans),Corporate and wholesale banking,MSME and business banking,
    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITEDIndiaPublic CompanyVehicle Finance (CV, PV, 2W/3W, tractors, construction equipment),Loan Against Property (LAP) and SME Secured Loans,Home Loans and Home Extensions,
    AXIS MUTUAL FUNDIndiaPrivate CompanyActively managed equity funds,Hybrid and asset allocation funds,Debt and money market funds,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PHC HOLDINGS CORPORATIONJapanPublic CompanyDiabetes Management,Diagnostic and Life Sciences,Healthcare Solutions (EMR, billing, pharmacy, wellness),
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
    AVANTOR, INC.United StatesPublic CompanyMaterials and consumables,Equipment and instrumentation,Services and specialty procurements,
    CRYOPORTUnited StatesPublic CompanyLife Sciences Services (logistics, biostorage, bioservices, consulting),Life Sciences Products (cryogenic freezers, dewars, accessories),IoT and digital monitoring solutions,
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    LABCORPUnited StatesPublic CompanyRoutine and chronic-disease diagnostics (chemistry, hematology, A1C, thyroid, PSA, urinalysis),Specialty and esoteric testing (gene-based, oncology, cardiovascular, endocrinology, infectious disease),Biopharma Laboratory Services and clinical trial support,
    EUROFINS SCIENTIFICLuxembourgPublic CompanyFood and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics,
    HAIER BIOMEDICALChinaPublic CompanyULT freezers and low-temperature storage,Pharmacy and vaccine refrigerators/freezers, cold rooms,Blood bank and transfusion chain equipment,
    HAMILTON COMPANYUnited StatesPublic Investment FirmFund-of-funds (primary and secondary),Direct credit,Direct and co-investments / buyouts,

    MAXCYTE, INC

    MAXCYTE, INC is a public company based in the United States that was founded in 1998 and currently employs 91 people.

    HDFC BANK

    HDFC BANK is a public company based in India that was founded in 1994 and currently employs 212,958 people.

    STANDARD CHARTERED

    STANDARD CHARTERED is a private company based in the United Kingdom that was founded in 1853 and currently employs 66,524 people.

    YES BANK

    YES BANK is a public company based in India that was founded in 2003 and currently employs 29,577 people.

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED

    CHOLAMANDALAM INVESTMENT AND FINANCE COMPANY LIMITED is a public company based in India that was founded in 1978 and currently employs 51,320 people.

    AXIS MUTUAL FUND

    AXIS MUTUAL FUND is a private company based in India that was founded in 2009.

    THERMO FISHER SCIENTIFIC INC.

    THERMO FISHER SCIENTIFIC INC. is a public company based in the United States that was founded in 1956 and currently employs 125,000 people.

    PHC HOLDINGS CORPORATION

    PHC HOLDINGS CORPORATION is a public company based in Japan that was founded in 1948 and currently employs 8,647 people.

    QIAGEN

    QIAGEN is a public company based in the Netherlands that was founded in 1984 and currently employs 5,500 people.

    MERCK KGAA

    MERCK KGAA is a public company based in Germany that was founded in 1668 and currently employs 59,077 people.

    AVANTOR, INC.

    AVANTOR, INC. is a public company based in the United States that was founded in 1904 and currently employs 13,500 people.

    CRYOPORT

    CRYOPORT is a public company based in the United States that was founded in 1999 and currently employs 688 people.

    AGILENT TECHNOLOGIES, INC.

    AGILENT TECHNOLOGIES, INC. is a public company based in the United States that was founded in 1999 and currently employs 18,000 people.

    LABCORP

    LABCORP is a public company based in the United States that was founded in 1995 and currently employs 66,385 people.

    EUROFINS SCIENTIFIC

    EUROFINS SCIENTIFIC is a public company based in Luxembourg that was founded in 1987 and currently employs 65,694 people.

    HAIER BIOMEDICAL

    HAIER BIOMEDICAL is a public company based in China that was founded in 2005 and currently employs 2,945 people.

    HAMILTON COMPANY

    HAMILTON COMPANY is a public investment firm based in the United States that was founded in 1991 and currently employs 785 people.

    North America vs. other regions

    HowNorth America compares to the other 3 regional blocs covered in this market.

    Europe
    ~USD 3037.4 Million · 9% wtd CAGR ·
    Asia Pacific
    ~USD 2567.8 Million · 9.6% wtd CAGR ·
    Latin America
    ~USD 555.4 Million · 8.6% wtd CAGR ·

    Countries within North America - compare and drill down

    Country2025 size (native)
    USUSD 2908.8 Million
    CanadaUSD 534.6 Million

    Country market size visualization

    US
    USD 2908.8 Million
    Canada
    USD 534.6 Million

    Reasons to Buy this Report

    • Market Size & Growth Data : Access precise 2025-2030 market valuations for North America ($3.3B-$5.2B) with country-level breakdowns for the US and Canada, enabling accurate revenue projections and investment planning.
    • Regional Competitive Intelligence : Understand North America's market dynamics, regulatory landscape, and competitive positioning relative to global markets, identifying opportunities in the fastest-growing precision medicine segment.
    • Country-Specific Insights : Detailed analysis of US ($2.9B) and Canadian ($534.6M) biobanking markets, including regional healthcare policies, infrastructure capabilities, and investment trends specific to each country.
    • Strategic Investment Guidance : Leverage comprehensive market forecasts and growth drivers to identify optimal entry points, partnership opportunities, and expansion strategies within North America's biobanking ecosystem.
    • Precision Medicine Trends : Gain insights into North America's leadership in genomic research, personalized medicine adoption, and emerging technologies in biobank operations to stay ahead of market evolution.

    Frequently asked questions

    What is the projected size of the North America biobanking market by 2030?

    The North America biobanking market is projected to reach $5,156.4 million by 2030, growing from $3,318.8 million in 2025.

    What is the CAGR for the North America biobanking market?

    The North America biobanking market is expected to grow at a compound annual growth rate (CAGR) of 9.2% between 2025 and 2030.

    What factors are driving growth in North America's biobanking market?

    Key drivers include rising healthcare expenditures, expanding clinical trial activities, precision medicine adoption, and increased investment in genomic research across North America.

    How does North America's regulatory environment impact biobanking?

    North America's FDA oversight and HIPAA compliance standards ensure quality, safety, and ethical practices in biobanking operations, supporting market credibility and growth.

    What role does precision medicine play in North America's biobanking market?

    Precision medicine initiatives in North America drive demand for diverse biological samples and advanced biobanking infrastructure to support personalized treatment development and clinical applications.

    RESEARCH METHODOLOGY

    This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:

    Biobanking Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Biobanking Market : Top-Down and Bottom-Up Approach

    Biobanking Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.

    Market Definition

    Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.

    Key Stakeholders

    • Academic & Research Institutes
    • Biobanks
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical and Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Forensics Labs
    • Government organizations
    • Private research firms
    • Hospitals and Diagnostic Laboratories

    Report Objectives

    • To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
    • To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market share and core competencies
    • To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:

    Geographical Analysis

    • Further breakdown of Rest of Europe biobanking market, by country
    • Further breakdown of Rest of Asia Pacific biobanking market, by country

    Comapany Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

     

    Get the Full Biobanking Market Report

    Full forecast, segment splits, and company analysis for all Biobanking Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status